A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Latest Information Update: 19 Mar 2025
At a glance
- Drugs INB-400 (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors IN8bio
- 13 Mar 2025 According an IN8bio media release, company has paused enrollment in the Phase 2 INB-400 glioblastoma program despite compelling data, to focus resources while exploring partnership and alternative funding opportunities.
- 12 Nov 2024 According an IN8bio media release, preliminary clinical data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- 12 Nov 2024 According an IN8bio media release, data from the study will be presented in a upcoming plenary oral presentation at the 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), being hosted November 21 - 24, 2024 in Houston,